Hunan Jiudian Pharmaceutical Co Ltd banner

Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705

Watchlist Manager
Hunan Jiudian Pharmaceutical Co Ltd Logo
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
Watchlist
Price: 12.85 CNY -0.7% Market Closed
Market Cap: ¥6.4B

P/FCFE

20.2
Current
22%
Cheaper
vs 3-y average of 25.8

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
20.2
=
Market Cap
¥7.7B
/
Free Cash Flow to Equity
¥319m

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
20.2
=
Market Cap
¥7.7B
/
Free Cash Flow to Equity
¥319m

Valuation Scenarios

Hunan Jiudian Pharmaceutical Co Ltd is trading below its 3-year average

If P/FCFE returns to its 3-Year Average (25.8), the stock would be worth ¥16.45 (28% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+124%
Average Upside
65%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 20.2 ¥12.85
0%
3-Year Average 25.8 ¥16.45
+28%
5-Year Average 45.2 ¥28.83
+124%
Industry Average 35.7 ¥22.77
+77%
Country Average 26.4 ¥16.83
+31%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
CN
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
6.4B CNY 20.2 13.7
US
Eli Lilly and Co
NYSE:LLY
908.9B USD 61.3 36
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 21 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 27.5 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 36.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 9.4 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 12.2 31.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD -766.6 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 24.3 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 24.3 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.9B USD 37.8 4 516.9
P/E Multiple
Earnings Growth PEG
CN
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
Average P/E: 472.3
13.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
32%
1.1
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
31.1
14%
2.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
4 516.9
648%
7

Market Distribution

In line with most companies in China
Percentile
42st
Based on 5 086 companies
42st percentile
20.2
Low
0.2 — 13.7
Typical Range
13.7 — 52.8
High
52.8 —
Distribution Statistics
China
Min 0.2
30th Percentile 13.7
Median 26.4
70th Percentile 52.8
Max 2 279 450.9

Hunan Jiudian Pharmaceutical Co Ltd
Glance View

Market Cap
6.4B CNY
Industry
Pharmaceuticals

Hunan Jiudian Pharmaceutical Co Ltd, nestled amidst the vibrant commercial landscape of China, exemplifies the dynamic evolution of the pharmaceutical industry within the region. Founded on the principles of innovation and resilience, the company has carved a niche by focusing on the development, production, and sale of a variety of active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates through an intricate web of research and development that is deeply aligned with the latest advancements in medical science. Central to its operations is a robust R&D facility that not only ensures high-standard quality control but also keeps the pipeline brimming with potential new products. This forward-thinking approach is critical, as it continually feeds the market with pharmaceuticals that cater to both chronic and acute health conditions, ranging from anti-infectives to cardiovascular drugs. The company capitalizes on a vertically integrated business model, which substantially aids in controlling cost and quality across all stages of production. By managing a seamless supply chain that extends from raw material procurement to drug distribution, Hunan Jiudian Pharmaceutical ensures both operational efficiency and market competitiveness. Revenue streams largely flow from the sale of its proprietary products in domestic and international markets, supported by a comprehensive marketing strategy and a broad distribution network. This pragmatic blend of science, strategy, and salesmanship allows the company not only to generate profits but also to contribute significantly to the global pharmaceutical framework, marking its presence as a formidable player in this ever-changing industry.

Intrinsic Value
11.83 CNY
Overvaluation 8%
Intrinsic Value
Price ¥12.85
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett